Pure autonomic failure is a rare neurodegenerative condition in which the body’s involuntary nervous system gradually stops working properly, most visibly causing a dangerous drop in blood pressure upon standing. People with PAF typically appear in midlife or later with dizziness, fainting, or near-fainting episodes when upright, but the disorder reaches well beyond blood pressure into bladder control, sexual function, sweating, and digestion.1PubMed Central. Pure Autonomic Failure What makes PAF especially interesting to researchers is that it sits at a crossroads: it shares a molecular signature with Parkinson’s disease and dementia with Lewy bodies, and a meaningful fraction of patients eventually develop one of those conditions.
What Happens in PAF
Your autonomic nervous system handles the background tasks you never think about: adjusting heart rate, routing blood flow when you stand, regulating temperature through sweating, moving food through your gut, and controlling the bladder. In PAF, the nerve fibers responsible for these jobs degenerate. The hallmark protein involved is alpha-synuclein, which misfolds and accumulates inside autonomic neurons, predominantly in the peripheral nervous system rather than the brain.2Mayo Clinic Proceedings. Pure Autonomic Failure This peripheral focus is what initially spares cognition and movement, distinguishing PAF from Parkinson’s disease or multiple system atrophy (MSA), where the brain takes the brunt of damage early on.
The most medically significant consequence is neurogenic orthostatic hypotension, a steep fall in blood pressure when you go from lying down to standing. In testing, patients with PAF have shown average drops in mean arterial pressure of roughly 54 mmHg upon head-up tilt, a fall severe enough to cause lightheadedness, tunnel vision, or outright fainting.3PubMed. Plasma norepinephrine responses to head-up tilt are misleading in autonomic failure Falls from syncope are a leading source of injury and hospitalization for these patients.
Symptoms Beyond Blood Pressure
Orthostatic hypotension gets the most clinical attention because it is the most immediately dangerous feature of PAF, but the broader symptom picture is often what erodes daily life most. A recent study found that health-related quality of life in PAF patients was significantly lower than in the general population, with the physical health domains hit hardest. About half of participants showed at least mild dependence in everyday activities, and urinary control was the single most affected function.4PubMed. Quality of life and disability in pure autonomic failure: More than a prodromal synucleinopathy
Bladder and sexual dysfunction are nearly universal. In one cohort, 96% of PAF patients reported lower urinary tract symptoms, with overactive bladder being the most common complaint (92%), followed by difficulty emptying the bladder (76%). Sexual dysfunction affected 84% of the group.5PubMed Central. Pelvic autonomic dysfunction is common in patients with pure autonomic failure Despite how prevalent these symptoms are, only a small minority in that study (16%) needed catheterization, suggesting that bladder problems tend to be bothersome but often manageable without invasive interventions.
Sweating abnormalities are another hallmark. Some patients gradually lose the ability to sweat over large areas of the body, a process that can start on one side and spread over years. One well-documented case began with reduced sweating on the left side of the face, then progressed to widespread loss of sweating throughout the body over a twelve-year period.6PubMed Central. A Case of Pure Autonomic Failure Initially Presenting with Hemihypohidrosis: Twelve-Year Follow-Up In rare instances the opposite can happen: one patient developed paradoxical sweating triggered by cool ambient temperatures, likely because remaining nerve terminals became hypersensitive to noradrenaline.7PubMed. Pure autonomic failure with cold induced sweating Gastrointestinal slowdown, including constipation and bloating, is common across synucleinopathies and PAF is no exception, though there is no standard way to directly verify enteric nerve damage in a clinical setting.
How PAF Is Diagnosed
There is no single blood test that confirms PAF. Diagnosis traditionally rests on documenting neurogenic orthostatic hypotension through tilt-table testing, then ruling out other causes of autonomic failure such as diabetes, amyloidosis, and autoimmune autonomic neuropathy. The clinical picture matters: if someone has autonomic failure without the movement problems of Parkinson’s or the cerebellar signs of MSA, and without an identifiable secondary cause, PAF becomes the working diagnosis.
Low plasma norepinephrine at rest is one supporting clue, but it is not foolproof. During head-up tilt, even PAF patients can show a rise in circulating norepinephrine, not because their nerves are releasing more of it, but because the body is clearing it from the bloodstream more slowly as blood pressure and cardiac output fall. Healthy people show a genuine increase in norepinephrine release during tilt. The distinction matters: measuring norepinephrine levels during postural change alone is not a reliable diagnostic test for autonomic failure.8PubMed. Plasma norepinephrine responses to head-up tilt are misleading in autonomic failure Patients who retain the pure autonomic failure phenotype without converting to another disease tend to have very low resting norepinephrine, slow resting heart rates, no REM sleep behavior disorder, and preserved sense of smell.9PubMed Central. Natural history of pure autonomic failure: A United States prospective cohort
Cardiac MIBG scintigraphy, an imaging test that visualizes sympathetic nerve terminals in the heart, shows abnormal uptake in most PAF patients. The pattern of reduced uptake and enhanced washout overlaps with what is seen in Parkinson’s disease and dementia with Lewy bodies, reflecting the shared underlying loss of cardiac sympathetic neurons.10PubMed. Cardiac MIBG scintigraphy in pure autonomic failure: A systematic review11PubMed. Reduced cardiac uptake and enhanced washout of 123I-MIBG in pure autonomic failure occurs conjointly with Parkinson’s disease and dementia with Lewy bodies
Skin Biopsy as a Diagnostic Tool
One of the more promising developments in PAF diagnosis is skin biopsy for phosphorylated alpha-synuclein. The same misfolded protein that accumulates in autonomic nerve fibers can be detected in tiny nerve endings in the skin. In a large multicenter study, skin biopsy detected phosphorylated alpha-synuclein in 100% of PAF patients tested (22 of 22), 93% of those with Parkinson’s disease, 98% with MSA, and 96% with dementia with Lewy bodies. Only about 3% of healthy controls tested positive.12JAMA. Skin Biopsy Detection of Phosphorylated α-Synuclein in Patients With Synucleinopathies Earlier, smaller work had also found phosphorylated alpha-synuclein in skin nerves of every PAF patient tested, with none detected in controls.13PubMed. Skin nerve misfolded α-synuclein in pure autonomic failure and Parkinson disease
Skin biopsy does more than just confirm that synucleinopathy is present. It can help distinguish PAF from MSA, which is clinically important because the two conditions have very different prognoses. PAF patients showed significantly higher skin synuclein scores than MSA patients, and a specific threshold on the scoring system could separate the two with 100% specificity and 82% sensitivity.14PubMed. Cutaneous phosphorylated-synuclein: an early diagnostic biomarker for pure autonomic failure The underlying reason ties back to where the disease strikes: PAF preferentially damages peripheral postganglionic nerve fibers, which run through the skin, while MSA tends to leave those peripheral fibers relatively intact and instead damages more centrally located neurons. Direct analysis of skin sympathetic fibers has confirmed that PAF patients show marked postganglionic sympathetic denervation compared to MSA patients, whose skin innervation is generally preserved.15Journal of Neurology, Neurosurgery & Psychiatry. Autonomic innervation in multiple system atrophy and pure autonomic failure
Phenoconversion and What It Means for Patients
Perhaps the most anxiety-producing aspect of a PAF diagnosis is the possibility of “phenoconversion,” meaning the disease evolves into a more recognizable condition with brain involvement. Because PAF shares its molecular basis with Parkinson’s disease, dementia with Lewy bodies, and MSA, it has increasingly been understood as a potential early stage of these illnesses rather than a permanently isolated entity.
The numbers depend on the study. In one large retrospective analysis of 318 patients meeting criteria for possible PAF, about 12% converted to another synucleinopathy. Among those converters, 22 developed MSA, 11 developed Parkinson’s or dementia with Lewy bodies, and 4 remained unclear.16PubMed Central. Pure autonomic failure: Predictors of conversion to clinical CNS involvement A prospective cohort that tracked patients more systematically found a higher conversion rate: out of 275 PAF patients, 67 (about 24%) phenoconverted, splitting roughly evenly between MSA and the Parkinson’s/dementia with Lewy bodies group.17PubMed Central. Predicting phenoconversion in pure autonomic failure The difference between 12% and 24% likely reflects how long and how closely patients are followed.
This means the majority of PAF patients do not convert, at least over the follow-up periods studied so far. And there are clues that help predict who might. Patients who retained stable PAF tended to have very low norepinephrine, slower heart rates, no REM sleep behavior disorder, and intact smell.18PubMed Central. Natural history of pure autonomic failure: A United States prospective cohort By contrast, REM sleep behavior disorder, where people physically act out dreams, appears to signal brainstem involvement and a higher chance of conversion. In one small case series, five out of eight PAF patients (63%) met diagnostic criteria for REM sleep behavior disorder when formally tested.19PubMed. A case series of REM sleep behavior disorder in pure autonomic failure
Emerging blood-based biomarkers add another layer. Neurofilament light chain, a protein released when nerve cells are damaged, was elevated at baseline only in PAF patients who later developed MSA, perfectly distinguishing them from those who went on to develop Parkinson’s or dementia with Lewy bodies as well as from non-converters.20PubMed Central. Alpha-Synuclein Oligomers and Neurofilament Light Chain Predict Phenoconversion of Pure Autonomic Failure If validated in larger studies, this could eventually give clinicians a way to identify the highest-risk patients before symptoms of brain involvement appear.
Two Distinct Pathways of Progression
Not all phenoconversion looks the same. Clinical and postmortem evidence points to two fundamentally different routes out of PAF, depending on where the synuclein pathology sits. The form of PAF that involves synucleinopathy within peripheral sympathetic neurons, with noradrenergic deficiency as the key feature, tends to convert to Parkinson’s disease or dementia with Lewy bodies. Critically, this form does not appear to convert to MSA.21PubMed Central. Different phenoconversion pathways in pure autonomic failure with versus without Lewy bodies The PAF patients who eventually develop MSA likely have a different underlying process from the start, one that damages central autonomic pathways rather than peripheral nerve endings.
This distinction matters practically. If a patient with PAF has clear evidence of peripheral sympathetic denervation (low norepinephrine, abnormal cardiac MIBG, high skin synuclein scores), their risk profile for conversion leans toward Parkinson’s or dementia with Lewy bodies rather than MSA. The finding also reinforces the idea that PAF is not a single disease but a clinical syndrome that may have more than one underlying mechanism.
Managing Orthostatic Hypotension
Treatment of PAF is entirely symptomatic since no therapy exists to stop the underlying nerve degeneration. The primary target is orthostatic hypotension, and management draws from both drug and non-drug strategies.
Non-pharmacological measures are the foundation. Simple physical countermaneuvers like leg crossing and squatting can meaningfully improve standing blood pressure. Rapid water drinking, roughly 480 mL consumed in under five minutes at room temperature, has also been shown to improve standing blood pressure and upright tolerance in patients with autonomic failure, with a similar effect regardless of whether the underlying cause was PAF or MSA.22JBI Evidence Synthesis. Effectiveness of non-pharmacological interventions to treat orthostatic hypotension in elderly people and people with a neurological condition: a systematic review Other practical steps include increasing salt and fluid intake, wearing compression garments on the abdomen and legs, eating smaller meals to avoid post-meal blood pressure dips, and rising slowly from bed.
When lifestyle measures are not enough, medications step in. Midodrine, which constricts blood vessels, has the strongest evidence base for raising standing blood pressure and reducing symptoms. Fludrocortisone, a synthetic steroid that promotes salt and water retention, is widely used but still lacks rigorous controlled trial data. Droxidopa, a synthetic amino acid that the body converts directly into norepinephrine, is approved for neurogenic orthostatic hypotension associated with primary autonomic failure including PAF.23PubMed Central. Droxidopa for Hypotension of Different Etiologies: Two Case Reports24PubMed. Drug treatment of orthostatic hypotension because of autonomic failure or neurocardiogenic syncope Other options that have shown benefit in smaller studies include octreotide, indomethacin, and ergotamine.
The Supine Hypertension Problem
One of the trickiest aspects of managing PAF is that the same patients who cannot maintain blood pressure while standing often develop dangerously high blood pressure while lying down. This supine hypertension is not a minor nuisance; it is associated with organ damage and produces overnight pressure-driven fluid loss through the kidneys, which worsens orthostatic hypotension the next morning by depleting blood volume.25PubMed. Management of hypertension in the setting of autonomic dysfunction
During the day, the best approach is simply avoiding lying flat. At night, raising the head of the bed by six to nine inches can help, but many patients need medication to keep nighttime blood pressure from climbing too high. Transdermal nitroglycerin patches or short-acting nifedipine at bedtime have both proven effective. The catch is that these patients are unusually sensitive to blood-pressure-lowering drugs, so doses need careful individual adjustment to avoid making orthostatic hypotension worse. Treating PAF therefore becomes a constant balancing act: enough blood pressure support to stand safely during the day, enough blood pressure control to protect organs at night.
Living with PAF as Its Own Condition
There has been a tendency in the research community to view PAF primarily through the lens of what it might become rather than what it already is. The phenoconversion question is scientifically compelling, but framing PAF only as a “prodromal synucleinopathy” risks downplaying its current impact. Recent quality-of-life data push back on that framing. Patients with PAF who never convert still experience significant disability. Physical health domains are particularly affected, and dependence on others for daily activities is common even without the cognitive or motor deterioration seen in Parkinson’s or dementia.26PubMed. Quality of life and disability in pure autonomic failure: More than a prodromal synucleinopathy
The bladder dysfunction, sexual dysfunction, exercise intolerance, heat sensitivity from impaired sweating, unpredictable fainting episodes, and constipation collectively reshape daily life in ways that rarely get captured in studies focused on conversion rates. Many patients restrict their activities to avoid syncope, stop driving, and limit social outings. The condition deserves clinical attention and research investment on its own terms, not only as a waypoint to something else.
Why REM Sleep Behavior Disorder Matters in PAF
Acting out dreams during sleep, sometimes violently, is a well-known early marker in Lewy body diseases. Its presence in PAF patients is worth noting because it suggests the synucleinopathy has already reached the brainstem, specifically the regions that normally suppress muscle movement during REM sleep. In one formal assessment, the majority of PAF patients tested positive for this disorder, which was higher than prior estimates had suggested.27PubMed. A case series of REM sleep behavior disorder in pure autonomic failure In the prospective natural history cohort, the absence of REM sleep behavior disorder was one of the features that characterized patients who stayed in the PAF category without converting.28PubMed Central. Natural history of pure autonomic failure: A United States prospective cohort
For patients and clinicians, this creates a practical consideration. A PAF patient who also has confirmed REM sleep behavior disorder likely warrants closer monitoring for early signs of parkinsonism or cognitive change. Conversely, a PAF patient with normal REM sleep, intact smell, and very low resting norepinephrine has a more reassuring profile, though no combination of markers can guarantee the disease will remain confined to the autonomic nervous system.
Smell Testing and Other Low-Tech Screening Tools
Loss of smell is one of the earliest non-motor features of Parkinson’s disease and dementia with Lewy bodies. In PAF, preserved olfaction appears to be a favorable sign, aligning with other markers of stable disease. Formal smell testing is inexpensive, painless, and can be done in an office visit. While no one would base a clinical decision on smell testing alone, pairing it with assessments of REM sleep, resting heart rate, and plasma norepinephrine creates a low-cost clinical profile that can help stratify risk without advanced imaging or invasive procedures. The small subset of PAF patients with preserved smell, no dream enactment, slow resting heart rates, and very low norepinephrine seem to be the patients most likely to stay as they are.29PubMed Central. Natural history of pure autonomic failure: A United States prospective cohort
The broader clinical challenge is that PAF remains rare enough that many general practitioners have never seen a case. Patients frequently spend years bouncing between cardiologists, urologists, and gastroenterologists before the unifying diagnosis is recognized. The sweating abnormalities are attributed to dermatological problems, the bladder symptoms to aging or prostate disease, and the blood pressure drops to dehydration or cardiac issues. Recognizing the pattern of multi-system autonomic failure without motor or cognitive signs is the key to reaching the right diagnosis, and that recognition often requires referral to a specialist in autonomic disorders.